Agenus to Present at BIO CEO & Investor Conference
February 06 2014 - 8:00AM
Business Wire
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing
novel immune system activating treatments for cancers and
infectious diseases, today announced that the company will be
presenting at the 16th Annual BIO CEO & Investor Conference on
Monday, February 10th at 9:30 am EST in the Conrad Room. Hosted by
the Biotechnology Industry Organization (BIO), the 16th Annual BIO
CEO & Investor Conference will take place February 10-11 at the
Waldorf Astoria in New York City.
Web Cast Information
The live and archived webcast of the company presentation will
be accessible from the company’s website at
www.agenusbio.com/webcast. Please log in approximately 5-10 minutes
before each event to ensure a timely connection. The archived
replay will be available on the Agenus website for one month
following the conference.
About Agenus
Agenus Inc. is a biotechnology company developing treatments for
cancers and infectious diseases. The company has multiple
immunotherapeutic products based on strong technology platforms
that are advancing through the clinic. Agenus’ technology is
further validated through partnerships with major pharmaceutical
companies, with several product candidates in late-stage clinical
trials with corporate partners. Between Agenus and its partners, 23
programs are in clinical development. For more information, please
visit www.agenusbio.com, or connect with the company on Facebook,
LinkedIn, Twitter and Google+. For more information, please visit
www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking
statements, including statements regarding clinical trial
activities, the publication of data, and the potential application
of the Company’s technologies and product candidates in the
prevention and treatment of diseases. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission for the period ended September
30, 2013. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this
document, and Agenus undertakes no obligation to update or revise
the statements. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Agenus’
business is subject to substantial risks and uncertainties,
including those identified above. When evaluating Agenus’ business
and securities, investors should give careful consideration to
these risks and uncertainties.
Media and Investor Contact:Agenus Inc.Jonae R. Barnes,
617-818-2985Vice PresidentInvestor Relations and Corporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024